AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
This guide identifies key asset categories to hold in a new crypto portfolio, with beginner friendly risk considerations.
27,914 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Floating-rate Treasuries have provided steadier income as rate volatility persists. This piece examines how USFR deli...
The spotlight in AI investing is shifting from screens to factories. The BOTZ ETF is positioning itself to ride a wav...
As markets swing in early 2026, three actively-managed ETFs are drawing inflows for steady income and downside protec...
A State Street strategist says the Fed will cut rates three times in 2026, a view that clashes with current market pr...
As AI accelerates, the stock narrative centers on NVIDIA, AMD, and Broadcom. This guide breaks down why each could de...
If you’re building a better payments stock long thesis, American Express and Visa offer different routes to durable c...
A 67-year-old single retiree with $920,000 could extend retirement beyond typical horizons if Social Security COLA re...
In Q1 2026, Duquesne Family Office quietly expanded its South American equity bets, signaling a macro-led stance that...
As coastal Florida draws more retirees, a 62-year-old with $1.3 million weighs whether the Boca Raton lifestyle can l...
A couple can retire at 65 in Colorado's Rockies on a $1.2 million nest egg by selecting affordable mountain towns and...
Chewy has faced a rough year, with shares falling and growth challenges ahead. Yet, a closer look under the hood show...